William Blair analyst Myles Minter initiated coverage of Argenx with an Outperform rating and no price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARGX:
- Argenx price target raised to EUR 450 from EUR 405 at Barclays
- Argenx to acquire PRV for $102M
- argenx Enters Into Agreement To Acquire Priority Review Voucher
- argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- Argenx price target raised to EUR 480 from EUR 470 at JPMorgan